Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
HighlightsCreative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
HighlightsCreative Biolabs has established a broad range of platforms for developing novel antibodies or equivalents. These cutting-edge technologies enable our scientists to meet your demands from different aspects and tailor the most appropriate solution that contributes to the success of your projects.
HighlightsWith deep understanding in antibody-related realms and extensive project experience, Creative Biolabs offers a variety of references to help you learn more about our capacities and achievements, including infographic, flyer, case study, peer-reviewed publications, and all kinds of knowledge that can assist your projects. You are also welcome to contact us directly for more specific solutions.
HighlightsGet a real taste of Creative Biolabs, one of the most professional custom service providers in the world. We are committed to providing highly customized comprehensive solutions with the best quality to advance your projects.
Highlights
| Protein Name | Adhesion G protein-coupled receptor D1 |
| Gene Name | ADGRD1 |
| Uniprot | Q6QNK2 (Human); Q80T32 (Mouse) |
| Synonym | PGR25; GPR133; G-protein coupled receptor 133; G-protein coupled receptor PGR25; probable G-protein coupled receptor 133 |
| Background | ADGRD1, also known as G-protein coupled receptor 133 (GPR133) or G-protein coupled receptor PGR25 (PGR25), is a protein encoded by the human GPR133 gene. It belongs to the adhesion-GPCR family which is characterized by an extended extracellular region with a variable number of protein domains coupled to a TM7 domain via a domain known as the GPCR-Autoproteolysis INducing (GAIN) domain. Moreover, it also has high basal activity with high expression levels at the cell surface. |
Creative Biolabs offers comprehensive range of membrane protein products empowers your unique research needs.
| CAT# | Product Name | Expression System | Protein Length | Solubilizing Agents |
| S01YF-1023-KX369 | NativeExtract™ Human ADGRD1 Membrane Protein (Full length, Super Nanodisc) | HEK293 cells | Full length | Native Nanodisc |
| Please for more products or customization | ||||
R***n: Creative Biolabs' ADGRD1 exhibits exceptional purity (>95%) validated by SDS-PAGE.
04/Nov/2023
K***os: Seamless custom production of truncated ADGRD1 with FLAG-tag.
21/Jun/2024
We provide tailored solutions to meet your specific requirements. Please for more services.
Gene Editing for ADGRD1 Dysregulation
Creative Biolabs offers gene editing services. The gene editing system represents a transformative approach to rectifying ADGRD1-associated genetic anomalies. By designing single-guide RNAs complementary to conserved regions of the ADGRD1 promoter or coding sequences, this methodology enables precise modulation of gene expression. Gene editing-based knockout of ADGRD1 attenuates aberrant G protein-coupled receptor signaling, suggesting therapeutic potential for disorders characterized by hyperactive ADGRD1 pathways. Creative Biolabs' proprietary single-guide RNA design algorithms ensure maximal on-target specificity, minimizing off-site edits.
AAV-Delivered RNA Interference for ADGRD1 Silencing
Creative Biolabs offers AAV-delivered RNA interference services. Adeno-associated virus (AAV) vectors engineered with tissue-specific promoters facilitate selective ADGRD1 knockdown in pathological tissues. For instance, intraventricular delivery of AAV-shRNA constructs targeting ADGRD1 in glioblastoma models reduced tumor proliferation by disrupting autocrine signaling loops. Creative Biolabs' capsid optimization platform enhances blood-brain barrier penetration, enabling robust CNS targeting—a critical advantage for neurological applications.
Epigenetic Activation via Lentiviral Systems
Creative Biolabs offers epigenetic activation services. Lentiviral activation systems, leveraging transcriptional activators, offer a novel strategy to upregulate ADGRD1 in hypoactive states. In fibrotic disease models, ADGRD1 overexpression suppressed TGF-β1-induced collagen deposition, highlighting its role in extracellular matrix homeostasis. Creative Biolabs' validated libraries include ADGRD1-specific modules for high-throughput screening of therapeutic candidates.
Creative Biolabs offers comprehensive and innovative services to drive the development of ADGRD1 cell therapy. Please for more services.
CAR-T Cells Targeting ADGRD1-Expressing Malignancies
Creative Biolabs offers CAR-T cell engineering services. CAR-T cells engineered with ADGRD1-specific scFv domains exhibit potent cytotoxicity against ADGRD1-positive solid tumors. In triple-negative breast cancer xenografts, these cells achieved >70% tumor regression by disrupting ADGRD1-mediated pro-survival signaling. Creative Biolabs' lentiviral transduction protocols optimize CAR expression while preserving T-cell functionality, ensuring clinical translatability.
iPSC-Derived Neurons with Modulated ADGRD1 Activity
Creative Biolabs offers iPSC-derived neurons with modulated ADGRD1 activity services. iPSCs differentiated into dopaminergic neurons with gene edited ADGRD1 loci provide a platform to model Parkinsonian phenotypes. These cells recapitulate ADGRD1-driven calcium dysregulation, enabling high-throughput screening of neuroprotective compounds. Creative Biolabs' iPSC differentiation kits ensure reproducible generation of ADGRD1-modified neural lineages.
Exosome-Mediated ADGRD1 Antagonist Delivery
Creative Biolabs offers exosome-mediated ADGRD1 antagonist delivery services. Exosomes loaded with ADGRD1-blocking peptides or antisense oligonucleotides offer a non-viral strategy to modulate receptor activity. In pulmonary hypertension models, systemic exosome administration reduced right ventricular hypertrophy by attenuating ADGRD1-dependent vasoconstriction. Creative Biolabs' exosome loading technologies achieve >90% payload encapsulation efficiency, enhancing therapeutic bioavailability.
ADGRD1's multifaceted roles in disease pathogenesis demand equally sophisticated therapeutic strategies. Creative Biolabs' end-to-end solutions empower researchers to accelerate ADGRD1-targeted innovation. Please feel free to to customize your ADGRD1 development pipeline with precision tools and unparalleled expertise. Leverage our 20-year legacy in protein research to transform conceptual frameworks into clinical breakthroughs.
All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.
